Brief Title
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Official Title
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Brief Summary
This phase II trial studies how well sirolimus and azacitidine works in treating patients
with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia. Sirolimus may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as azacitidine, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing. Sirolimus and
azacitidine may kill more cancer cells.
Detailed Description
PRIMARY OBJECTIVE:
I. To characterize the rate of response to azacitidine and sirolimus in adults with high-risk
myelodysplastic syndrome (MDS), or relapsed or refractory acute myeloid leukemia (AML) or
those unable or unwilling to tolerate high dose chemotherapy.
SECONDARY OBJECTIVES:
I. To determine the pharmacodynamic effect of sirolimus on inhibition of mammalian target of
rapamycin (mTOR) signaling in adults with high-risk MDS, or relapsed or refractory AML or
those unable or unwilling to tolerate high dose chemotherapy.
II. To determine the safety and tolerability of sirolimus and azacitidine in adults with
high-risk MDS, or relapsed or refractory AML or those unable or unwilling to tolerate high
dose chemotherapy.
III. To determine the progression free survival and overall survival in adults with high-risk
MDS, or relapsed or refractory AML or those unable or unwilling to tolerate high dose
chemotherapy.
IV. To determine if the quality of life of patients is improved with the combination of
azacitidine and sirolimus when compared to historical controls of azacitidine alone.
OUTLINE:
Patients receive sirolimus orally (PO) on days 1-10 or 1-12 and azacitidine intravenously
(IV) on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of
disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Rate of response
Secondary Outcome
Toxicity referring to toxic events during the full course of treatment that are attributed as possibly, probably or definitely due to treatment, graded according to the National Institutes of Health (NIH) Common Toxicity Criteria (CTC) v. 4.0
Condition
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Intervention
Sirolimus
Study Arms / Comparison Groups
High risk Myleodysplastic Syndrome (MDS)
Description: Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
57
Start Date
July 8, 2013
Completion Date
December 2023
Primary Completion Date
December 2023
Eligibility Criteria
Inclusion Criteria:
1. Patients must have a diagnosis of one of the following:
- MDS (Arm A): High-risk MDS defined as: >5% blasts in bone marrow and/or the
following cytogenetic categories: presence of inv(3)/t(3q)/del(3q), -7/del(7q),
complex cytogenetics (3 or more abnormalities)
- AML (Arm B): Relapsed/refractory/unable to tolerate conventional chemotherapy
- MDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who
meet criteria for either Arm A or Arm B but have been treated or are currently
treated with Azacitibine *Note: As of July 2018, only high risk MDS patients will
be eligible as Arm B is closed. As of October 2017, those patients with MDS who
have received prior treatment will now be enrolled in Arm A as Arm C is closed.
2. Patients must be ≥ 18 years old
3. Patients must have an ECOG performance status of <= 2 (see Attachment 1).
4. Patients must have a life expectancy of at least 4 weeks.
5. Patients must be able to consume oral medication.
6. Patients must have completed any radiotherapy four weeks prior to study entry, 0-2
weeks for local palliative XRT (small port).
7. Patients must have recovered from the toxic effects of any prior chemotherapy to <
Grade 2 (except for alopecia).
8. Required initial laboratory values: Creatinine≤ 2.0mg/dL; total or direct bilirubin ≤
1.5mg/dL (if not due to the leukemia itself or known Gilbert's Syndrome);(as
documented by treating physician) SGPT(ALT) ≤ 3xULN; glucose <200 mg/dL, negative
pregnancy test for women of child-bearing potential.
9. Patients must be able to sign consent and be willing and able to comply with scheduled
visits, treatment plan and laboratory testing.
10. Patients may have had a prior stem cell transplant (autologous or allogeneic), however
they may not have active GvHD, nor be on any immunosuppression
Exclusion Criteria:
1. Patients must not be receiving any chemotherapy agents (except Hydroxyurea)
- Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not
systemic and only isolated to the central nervous system).
- Patients can not have received more than 3 prior lines of therapy for their
hematologic malignancy. Patient may have previously had azacitidine or decitabine
will be eligible to enroll on Arm A (MDS)
2. Patients must not be receiving growth factors.
3. Patients with a current second malignancy requiring systemic therapy, other than
non-melanoma skin cancers, are not eligible. If a patient has had a prior second
malignancy that is not currently requiring active treatment, the patient will be
considered eligible.
4. Patients with uncontrolled high blood pressure, unstable angina, symptomatic
congestive heart failure, myocardial infarction within the past 6 months or serious
uncontrolled cardiac arrhythmia are not eligible.
5. Patients may not take any of the following medications while on study, but will be
considered eligible if medication is discontinued 72 hrs prior to first dose of
Sirolimus:
- Carbamazepine (e.g. Tegretol)
- Rifabutin (e.g. Mycobutin)
- Rifampin (e.g. Rifadin)
- Rifapentine (e.g. Priftin)
- St. John's Wort- may decrease effects of sirolimus by decreasing the amount of
sirolimus in the body
- Clarithromycin (e.g. Biaxin)
- Cyclosporin e.g. (Neoral or Sandimmune)
- Diltiazem (e.g. Cardizem)
- Erythromycin (e.g. Akne-Mycin, Ery-Tab)
- Itraconazole (e.g. Sporanox)
- Fluconazole (e.g. Diflucan)
- Ketoconazole (e.g. Nizoral)
- Telithromycin (e.g. Ketek)
- Verapamil (e.g. Calan SR, Isoptin, Verelan)
- Voriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing
the amount of this medicine in the body. Can take 72 hours after last dose of
Sirolimus
- Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side
effects in patients on sirolimus.
6. Patients with known HIV positivity or AIDS-related illness are not eligible.
7. Patients with other severe concurrent disease which in the judgment of the
investigator would make the patient inappropriate for entry into this study are
ineligible.
8. Patients must not have received any investigational agents within 21days of study
entry.
9. Patients must not be pregnant or breastfeeding. Pregnancy tests must be obtained for
all females of child-bearing potential. Pregnant or lactating patients are ineligible
for this study due to the unknown human fetal or teratogenic toxicities of rapamycin.
Males or females of reproductive age may not participate unless they have agreed to
use an effective contraceptive method.
10. Patients who have uncontrolled infection are not eligible. Patients must have any
active infections under control. Fungal disease must be stable for at least 2 weeks
before study entry. Patients with bacteremia must have documented negative blood
cultures prior to study entry.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Margaret Kasner, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01869114
Organization ID
12D.587
Secondary IDs
2012-50
Responsible Party
Sponsor
Study Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Study Sponsor
Margaret Kasner, MD, Principal Investigator, Sidney Kimmel Cancer Center at Thomas Jefferson University
Verification Date
February 2023